Get the Stockscreener App
14.42
0.84%
0.12
After Hours:
14.42
Zymeworks Inc. stock is traded at $14.42, with a volume of 333.28K.
It is up +0.84% in the last 24 hours and up +11.52% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$14.30
Open:
$14.34
24h Volume:
333.28K
Relative Volume:
0.72
Market Cap:
$983.92M
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
5.15
EPS:
2.8
Net Cash Flow:
$-96.01M
1W Performance:
-0.89%
1M Performance:
+11.52%
6M Performance:
+65.37%
1Y Performance:
+69.55%
1-Day Range:
$14.06
$14.60
1-Week Range:
$13.40
$15.00
52-Week Range:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.42 | 983.92M | 62.71M | -112.51M | -96.01M | 2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Bloom Burton Estimates Zymeworks FY2024 Earnings - MarketBeat
HC Wainwright Reaffirms Neutral Rating for Zymeworks (NYSE:ZYME) - MarketBeat
In-Depth Examination Of 9 Analyst Recommendations For Zymeworks - Benzinga
FDA approves cancer drug developed by B.C.'s Zymeworks - Head Topics
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework - Benzinga
Zymeworks to Showcase Innovations at Investor Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - Financial Post
Zymeworks to Present at Major Healthcare Conferences, Announces R&D Day for Pipeline Updates | ZYME Stock News - StockTitan
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for - GlobeNewswire
Zymeworks' Ziihera Wins FDA Approval: First Dual HER2 Cancer Drug Shows 52% Response Rate | ZYME Stock News - StockTitan
Leerink Partners Upgrades Zymeworks (ZYME) - MSN
Redmile Group, LLC Adjusts Stake in Zymeworks Inc - GuruFocus.com
Zymeworks stock soars to 52-week high, hits $17.29 By Investing.com - Investing.com Australia
Zymeworks stock soars to 52-week high, hits $17.29 - Investing.com India
Zymeworks (NYSE:ZYME) Stock Rating Upgraded by Leerink Partners - Defense World
FY2024 EPS Estimates for Zymeworks Lifted by Leerink Partnrs - MarketBeat
Analysts Update Their Estimates For Zymeworks BC Inc - Stocks Register
Q4 Earnings Estimate for Zymeworks Issued By Leerink Partnrs - Defense World
Zymeworks (NYSE:ZYME) Raised to Strong-Buy at Leerink Partnrs - Defense World
Leerink Partnrs Forecasts Zymeworks' Q4 Earnings (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking - Simply Wall St
Zymeworks (NYSE:ZYME) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink lifts Zymeworks stock target on pipeline progress By Investing.com - Investing.com Nigeria
Leerink lifts Zymeworks stock target on pipeline progress - Investing.com
Zymeworks (NYSE:ZYME) Upgraded by Leerink Partners to "Outperform" Rating - MarketBeat
Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours - Clinical Trials Arena
Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $18.00 - Defense World
Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire
Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - The Manila Times
Zymeworks (NYSE:ZYME) Sets New 52-Week High Following Analyst Upgrade - Defense World
Zymeworks stock soars to 52-week high of $14.08 amid robust gains - Investing.com Canada
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (NYSE:ZYME) Cut to Equal Weight at Wells Fargo & Company - Defense World
Zymeworks’ (ZYME) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Zymeworks (NYSE:ZYME) Price Target Raised to $18.00 at Citigroup - MarketBeat
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Simply Wall St
Wells Fargo Downgrades Zymeworks (ZYME) - MSN
Zymeworks (NYSE:ZYME) Shares Gap Down – Here’s What Happened - Defense World
Zymeworks Inc. (NYSE:ZYME) Q3 2024 Earnings Call Transcript - Insider Monkey
Zymeworks Q4 2024 Earnings Preview - MSN
Zymeworks to Spotlight Innovations at Investor Conferences - MSN
Earnings call: Zymeworks reports Q3 2024 results and pipeline progress - Investing.com
Zymeworks (NYSE:ZYME) Shares Gap DownHere's Why - MarketBeat
Zymeworks stock downgraded at Wells Fargo (ZYME:NASDAQ) - Seeking Alpha
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook - Simply Wall St
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year - Yahoo Finance
HC Wainwright Reiterates Neutral Rating for Zymeworks (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):